Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU599943B2 - Fusion proteins with a eukaryotic ballast portion - Google Patents
[go: Go Back, main page]

AU599943B2 - Fusion proteins with a eukaryotic ballast portion - Google Patents

Fusion proteins with a eukaryotic ballast portion

Info

Publication number
AU599943B2
AU599943B2 AU66760/86A AU6676086A AU599943B2 AU 599943 B2 AU599943 B2 AU 599943B2 AU 66760/86 A AU66760/86 A AU 66760/86A AU 6676086 A AU6676086 A AU 6676086A AU 599943 B2 AU599943 B2 AU 599943B2
Authority
AU
Australia
Prior art keywords
fusion proteins
eukaryotic
ballast portion
amino
ballast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU66760/86A
Other versions
AU6676086A (en
Inventor
Paul Habermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU6676086A publication Critical patent/AU6676086A/en
Application granted granted Critical
Publication of AU599943B2 publication Critical patent/AU599943B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Suitable as "ballast portion" for fusion proteins is a part of the amino-acid sequence of interleukin-2 (IL-2) which comprises considerably less than 100 amino acids. It is advantageous to start from a synthetic IL-2 gene which is divided by unique cleavage sites into six segments of which up to three can be linked in any desired sequence by the building block principle. Specific constructions allowing the solubility of the fusion protein to be varied are possible.
AU66760/86A 1985-12-21 1986-12-19 Fusion proteins with a eukaryotic ballast portion Expired AU599943B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3545565 1985-12-21
DE3545565 1985-12-21
DE3636903 1986-10-30
DE19863636903 DE3636903A1 (en) 1985-12-21 1986-10-30 FUSION PROTEINS WITH EUKARYOTIC BALLASTES

Publications (2)

Publication Number Publication Date
AU6676086A AU6676086A (en) 1987-06-25
AU599943B2 true AU599943B2 (en) 1990-08-02

Family

ID=25839208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66760/86A Expired AU599943B2 (en) 1985-12-21 1986-12-19 Fusion proteins with a eukaryotic ballast portion

Country Status (16)

Country Link
EP (1) EP0229998B1 (en)
JP (2) JP2553058B2 (en)
KR (1) KR950000301B1 (en)
AT (1) ATE78296T1 (en)
AU (1) AU599943B2 (en)
CA (1) CA1339894C (en)
DE (1) DE3636903A1 (en)
DK (1) DK168823B1 (en)
ES (1) ES2033678T3 (en)
FI (1) FI93734C (en)
GR (1) GR3005985T3 (en)
HU (1) HU209747B (en)
IE (1) IE58935B1 (en)
IL (1) IL81018A (en)
NO (1) NO175003C (en)
PT (1) PT83973B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637139B2 (en) * 1985-12-21 1993-05-20 Hoechst Aktiengesellschaft Gm-csf protein, its derivatives, the preparation of proteins of this type, and their use

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3844211A1 (en) * 1988-12-29 1990-07-05 Hoechst Ag NEW INSULINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
FR2643646B1 (en) * 1989-02-27 1993-09-17 Pasteur Institut EXPRESSION OF NUCLEOTIDES SEQUENCES ENCODING FOR GAS VESICLES
CU22222A1 (en) * 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
DE3942580A1 (en) * 1989-12-22 1991-06-27 Basf Ag METHOD FOR PRODUCING HIRUDINE
DE4105480A1 (en) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
PT821006E (en) 1996-07-26 2004-09-30 Aventis Pharma Gmbh INSULIN DERIVATIVES WITH ENHANCED ZINC LINK
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE102006031955A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Process for the preparation of dibasic B chain end insulin analogs
DE102006031962A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
RS59913B1 (en) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
CN102596175A (en) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 Aqueous insulin preparations containing methionine
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (en) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
PL2611458T3 (en) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (en) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland PHARMACEUTICAL COMBINATION FOR USE IN GLUCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK108685A (en) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co GROWTH FACTOR I
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637139B2 (en) * 1985-12-21 1993-05-20 Hoechst Aktiengesellschaft Gm-csf protein, its derivatives, the preparation of proteins of this type, and their use

Also Published As

Publication number Publication date
CA1339894C (en) 1998-06-02
FI93734C (en) 1995-05-26
NO175003B (en) 1994-05-09
IL81018A (en) 1992-03-29
EP0229998A2 (en) 1987-07-29
GR3005985T3 (en) 1993-06-07
NO175003C (en) 1994-08-17
JPS62167799A (en) 1987-07-24
DE3636903A1 (en) 1987-07-02
ES2033678T3 (en) 1993-04-01
KR870006187A (en) 1987-07-09
DK619186A (en) 1987-06-22
PT83973A (en) 1987-01-01
JPH08187089A (en) 1996-07-23
FI865187L (en) 1987-06-22
DK619186D0 (en) 1986-12-19
FI93734B (en) 1995-02-15
FI865187A0 (en) 1986-12-18
DK168823B1 (en) 1994-06-20
JP2774260B2 (en) 1998-07-09
IE863334L (en) 1987-06-21
KR950000301B1 (en) 1995-01-13
JP2553058B2 (en) 1996-11-13
PT83973B (en) 1989-07-31
HUT44614A (en) 1988-03-28
EP0229998A3 (en) 1988-08-03
HU209747B (en) 1994-10-28
IL81018A0 (en) 1987-03-31
ATE78296T1 (en) 1992-08-15
AU6676086A (en) 1987-06-25
EP0229998B1 (en) 1992-07-15
IE58935B1 (en) 1993-12-01
NO865192L (en) 1987-06-22
NO865192D0 (en) 1986-12-19

Similar Documents

Publication Publication Date Title
AU599943B2 (en) Fusion proteins with a eukaryotic ballast portion
AU6733487A (en) Mammalian interleukin-4
AU595221B2 (en) Fusion proteins, a process for their preparation and their use
AU573523B2 (en) Functional human urokinase proteins
ES2078229T3 (en) PROCEDURE FOR THE PREPARATION OF A POLYPEPTIDE SIMILAR TO MOTILINE AND ITS EXPRESSION.
GB9222758D0 (en) Proteins and nucleic acids